

Hans Prozesky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2258026/publications.pdf>

Version: 2024-02-01

81
papers

14,872
citations

94433

37
h-index

69250

77
g-index

84
all docs

84
docs citations

84
times ranked

13816
citing authors

#	ARTICLE	IF	CITATIONS
1	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	27.0	3,760
2	A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. New England Journal of Medicine, 2001, 345, 1667-1675.	27.0	2,873
3	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
4	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	27.0	753
5	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	27.0	480
6	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases, 2021, 73, e2005-e2015.	5.8	405
7	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	27.0	339
8	Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies. PLoS Medicine, 2013, 10, e1001418.	8.4	330
9	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine, 2021, 9, 924-932.	10.7	218
10	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
11	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	27.0	205
12	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Medicine, 2012, 9, e1001304.	8.4	199
13	Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. Aids, 2010, 24, 2263-2270.	2.2	198
14	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
15	Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health, 2007, 7, 63.	2.9	160
16	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	2.1	142
17	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. The Lancet Global Health, 2021, 9, e1216-e1225.	6.3	131
18	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 428-437.	2.1	119

#	ARTICLE	IF	CITATIONS
19	A Dimorphic Fungus Causing Disseminated Infection in South Africa. New England Journal of Medicine, 2013, 369, 1416-1424.	27.0	118
20	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2325-2335.	27.0	112
21	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2313-2324.	27.0	108
22	Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV, 2021, 8, e554-e567.	4.7	105
23	Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. Aids, 2011, 25, 1761-1769.	2.2	98
24	Outcomes of laboratory-confirmed <scp>SARS-CoV</scp>-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Tropical Medicine and International Health, 2022, 27, 564-573.	2.3	94
25	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 524-532.	2.1	88
26	Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. Clinical Infectious Diseases, 2015, 61, 1004-1012.	5.8	68
27	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	2.0	60
28	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the leDEA Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 319-329.	2.1	58
29	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. JAMA Cardiology, 2021, 6, 706.	6.1	53
30	Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 547-554.	2.1	51
31	Twelve-year mortality in adults initiating antiretroviral therapy in South Africa. Journal of the International AIDS Society, 2017, 20, 21902.	3.0	50
32	Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. International Journal of Cancer, 2014, 135, 2644-2652.	5.1	48
33	Where do HIV-infected adolescents go after transfer? — Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform. Journal of the International AIDS Society, 2017, 20, 21668.	3.0	45
34	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. Pediatric Infectious Disease Journal, 2009, 28, 1125-1127.	2.0	44
35	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	5.8	44
36	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the leDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 653-60.	0.6	44

#	ARTICLE	IF	CITATIONS
37	AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. Open Forum Infectious Diseases, 2017, 4, ofx186.	0.9	41
38	Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health, 2020, 8, e1326-e1334.	6.3	40
39	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. Pediatric Infectious Disease Journal, 2016, 35, e164-e170.	2.0	38
40	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. Journal of the International AIDS Society, 2017, 20, 21327.	3.0	38
41	A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. Journal of the International AIDS Society, 2015, 18, 20628.	3.0	37
42	CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. Journal of Epidemiology and Community Health, 2016, 70, 549-555.	3.7	34
43	Implementation of "Treat-All" at adult <scp>HIV</scp> care and treatment sites in the Global le<scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	3.0	32
44	Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV, the, 2015, 2, e368-e375.	4.7	29
45	Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa. Journal of the International AIDS Society, 2020, 23, e25546.	3.0	27
46	Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 775-783.	1.2	22
47	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 142-145.	2.1	21
48	CD4 Count Slope and Mortality in HIV-Infected Patients on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 34-41.	2.1	21
49	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPEROR-Preserved</scp> trial. European Journal of Heart Failure, 2021, 23, 1798-1799.	7.1	21
50	Tuberculosis and the risk of opportunistic infections and cancers in <scp>HIV</scp>-infected patients starting <scp>ART</scp> in Southern Africa. Tropical Medicine and International Health, 2013, 18, 194-198.	2.3	20
51	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
52	The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: a cohort study using linked electronic health records. Epidemiology and Psychiatric Sciences, 2021, 30, e37.	3.9	20
53	The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. American Journal of Epidemiology, 2020, 189, 811-819.	3.4	19
54	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 146-154.	2.1	15

#	ARTICLE	IF	CITATIONS
55	Life expectancy trends in adults on antiretroviral treatment in South Africa. <i>Aids</i> , 2016, 30, 2545-2550.	2.2	15
56	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 30-38.	1.3	14
57	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. <i>Aids</i> , 2013, 27, 2225-2232.	2.2	13
58	Characterizing the double-sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. <i>Journal of the International AIDS Society</i> , 2020, 23, e25447.	3.0	13
59	Tenofovir in Second-Line ART in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 41-48.	2.1	12
60	Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?. <i>Aids</i> , 2017, 31, 147-157.	2.2	12
61	Leadership and early strategic response to the SARS-CoV- 2 pandemic at a COVID-19 designated hospital in South Africa. <i>South African Medical Journal</i> , 2020, 110, 463-465.	0.6	11
62	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. <i>International Journal of Epidemiology</i> , 2015, 44, 251-263.	1.9	10
63	<i>Bartonella</i> species as a cause of culture-negative endocarditis in South Africa. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1873-1879.	2.9	9
64	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, e110-e119.	2.1	8
65	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. <i>American Journal of Epidemiology</i> , 2018, 187, 1990-2001.	3.4	8
66	Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update?. <i>Open Heart</i> , 2022, 9, e001856.	2.3	8
67	Recording of HIV Viral Loads and Viral Suppression in South African Patients Receiving Antiretroviral Treatment: A Multicentre Cohort Study. <i>Antiviral Therapy</i> , 2020, 25, 257-266.	1.0	7
68	Combined Antiretroviral Treatment Initiation During Hospitalization: Outcomes in South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, 105-106.	2.1	6
69	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25200.	3.0	6
70	Clinical evolution, management and outcomes of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: a research protocol. <i>BMJ Open</i> , 2020, 10, e039455.	1.9	6
71	Causes of infective endocarditis in the Western Cape, South Africa: a prospective cohort study using a set protocol for organism detection and central decision making by an endocarditis team. <i>BMJ Open</i> , 2021, 11, e053169.	1.9	6
72	Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic.. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 27, .	0.6	6

#	ARTICLE	IF	CITATIONS
73	Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes. <i>BMJ Open</i> , 2018, 8, e017405.	1.9	5
74	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. <i>Antiviral Therapy</i> , 2013, 19, 521-525.	1.0	4
75	Extending Visit Intervals for Clinically Stable Patients on Antiretroviral Therapy: Multicohort Analysis of HIV Programs in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 439-447.	2.1	3
76	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 413-416.	2.1	2
77	Regression discontinuity analysis demonstrated varied effect of Treat-All on CD4 testing among Southern African countries. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 101-110.	5.0	1
78	Invasive fungal infections, other than <i>Candida</i> and <i>Cryptococcus</i> , from 2008 to 2011, at Tygerberg Hospital in the Western Cape, South Africa. <i>International Journal of Infectious Diseases</i> , 2012, 16, e323.	3.3	0
79	Early Surgery Determines Prognosis in Patients with IE: Outcome of Patients Managed by an Endocarditis Team - a Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
80	Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral therapy: A prospective multicohort study from southern Africa.. <i>Journal of Clinical Oncology</i> , 2011, 29, 1589-1589.	1.6	0
81	Record linkage augments cancer ascertainment in HIV cohorts in South Africa. <i>International Journal of Population Data Science</i> , 2017, 1, .	0.1	0